

On page 62, line 17, please change "(SEQ. ID. NO. __)" to --(SEQ. ID. NO. 75)--.

On page 62, line 18, please change "(SEQ. ID. NO. __)" to --(SEQ. ID. NO. 76)--.

On page 62, line 21, please change "(SEQ. ID. NO. __)" to --(SEQ. ID. NO. 77)--.

On page 62, line 22, please change "(SEQ. ID. NO. __)" to --(SEQ. ID. NO. 78)--.

On page 62, line 25, please change "(SEQ. ID. NO. __)" to --(SEQ. ID. NO. 79)--.

On page 62, line 26, please change "(SEQ. ID. NO. __)" to --(SEQ. ID. NO. 81)--.

On page 62, line 29, please change "(SEQ. ID. NO. __)" to --(SEQ. ID. NO. 82)--.

On page 62, line 30, please change "(SEQ. ID. NO. __)" to --(SEQ. ID. NO. 83)--.

IN THE CLAIMS:

SUBB 1. (Amended) A chimeric adenovirus comprising at least a part of a fiber protein of [an] a first adenovirus serotype providing the chimeric virus with a desired host range and at least a part of a penton or hexon protein from [another less antigenic] a second adenovirus serotype that is less antigenic in a human than the first adenovirus serotype resulting in a [less antigenic] chimeric adenovirus that is less antigenic in a human than the first adenovirus serotype.

a 2. (Amended) A recombinant vector derived from an adenovirus comprising at least one ITR and a packaging signal having an insertion site for a nucleic acid sequence of interest, and further having an insertion site for functionally inserting a gene encoding a penton and/or a hexon protein of a first serotype of adenovirus and having an insertion site for a gene encoding a fiber protein of a second adenovirus of a different serotype, wherein the gene encoding the penton and/or hexon protein encodes a penton and/or hexon protein from an adenovirus serotype less antigenic in a human than the second adenovirus serotype.

Please cancel claims 4, 5, 6, 7 and 8 without prejudice or disclaimer.

506 82 9. (Amended) A method for producing a chimeric adenovirus having [a desired host range and diminished antigenicity] immunological properties determined by a hexon and/or penton of a first adenovirus serotype and a desired host range determined by a fiber of a second adenovirus serotype, said method comprising

providing a recombinant vector derived from an adenovirus comprising at least one ITR and a packaging signal having an insertion site for a nucleic acid sequence of interest, and further having an insertion site for functionally inserting a gene encoding a penton and/or a hexon protein of [a] the first serotype of adenovirus and having an insertion site for a gene encoding a fiber protein of [a] the second adenovirus [of a different serotype];

inserting into said vector at least a functional part of a penton or hexon protein derived from [an] the first adenovirus serotype having relatively low antigenicity as compared with the second adenovirus serotype,

inserting at least a functional part of a fiber protein derived from [an] the second adenovirus serotype having the desired host range;

transfecting said vector in a packaging cell [according to claim 4]; and
producing chimeric viral particles.

10. (Amended) [A]The method according to claim 9, wherein the reduced antigenicity is a diminished capability, as compared with the first adenovirus serotype, to raise neutralizing antibodies.

Please cancel claim 12 without prejudice or disclaimer.

Remarks

The Office Action mailed 1 February 2000 has been received and reviewed. Claims 1 through 12 are pending in the application. All stand rejected. The application is to be amended as previously set forth. Claims 4-8, and 12 are to be canceled without prejudice or disclaimer in order to focus the prosecution of the instant application. All amendments (including the cancellation of